API | ripasudil

ripasudil (Glanatec) Report issue

Small molecule Experimental

DrugBank Drug Central KEGG PubChem

Active Ingredient History

NOW

Now

Ripasudil, a derivative of fasudil, is a rho kinase inhibitor drug used for the treatment of glaucoma and ocular hypertension. ^Wikipedia

Chemistry

SMILES: C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12
InChIKey: QSKQVZWVLOIIEV-NSHDSACASA-N
Mol. Mass: 323.39
ALogP: 1.75 Partition coefficient
ChEMBL Molecule:
ripasudil

More Chemistry

Pharmacology

Mechanisms of Action:
- Rho-associated protein kinase 1 (Homo sapiens) ^UniProt
- Rho-associated protein kinase 2 (Homo sapiens) ^UniProt
- Rho-associated protein kinase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

glanatec | glanatec ophthalmic solution | ripasudil | ripasudil hcl | ripasudil hydrochloride | ripasudil hydrochloride hydrate

Organizations (19)

Research & Development (19)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (1)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Cataract (Phase 3)

Corneal Diseases (Phase 2)

Corneal Edema (Phase 1)

Corneal Endothelial Cell Loss (Phase 2)

Endothelial Cells (Phase 1)

Fuchs' Endothelial Dystrophy (Phase 4)

General Surgery (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Macular Edema (Phase 1)

Ocular Hypertension (Phase 3)

Retinopathy of Prematurity (Phase 1/Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial Organizations: 19

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue